1-(3-chloro-4-pyridinyl)-1-ethanol | 886856-92-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(3-chloro-4-pyridinyl)-1-ethanol
• 英文别名: 1-(3-Chloropyridin-4-yl)ethanol
• CAS: 886856-92-4
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: JQOWLEAPTKFXJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

文献信息

• [EN] METHOD FOR PREPARING INDAZOLE COMPOUND AND USE THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ D'INDAZOLE ET SON UTILISATION<br/>[ZH] 吲唑类化合物的制备方法和用途
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2017008708A1

  公开（公告）日：2017-01-19

  本发明提供了一种吲唑类化合物的制备方法和用途，具体地，本发明提供了一种如下式(I)所示的化合物，其中，各基团的定义如说明书中所述。本发明化合物具有优异的酪氨酸激酶抑制活性，相较于现有技术中的化合物，本发明化合物具有更低的抑制浓度，故能够用于制备一系列治疗与酪氨酸激酶活性相关的疾病的药物。
• NOVEL FUSED IMIDAZOLE DERIVATIVE
  申请人：MSD K.K.

  公开号：EP1813613B1

  公开（公告）日：2012-12-19
• Novel Fused Imidazole Derivative
  申请人：Sato Yoshiyuki

  公开号：US20080103136A1

  公开（公告）日：2008-05-01

  The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A 1 and A 2 , are each a nitrogen atom, and the like; X 2 , X 3 , X 4 , and X 5 are all carbon atoms, or alternatively any one of X 2 , X 3 , X 4 , and X 5 is a nitrogen atom and the rest are all carbon atoms; R 1 is a hydrogen atom, or the like; R 2 , R 3 , R 4 , and R 5 , are each a hydrogen atom, or the like; R 6 and R 6 ′, are each a hydrogen atom, and the like; R 7 is an aryl group and the like; and R 8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.
• TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20210171500A1

  公开（公告）日：2021-06-10

  The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
• US8030327B2
  申请人：——

  公开号：US8030327B2

  公开（公告）日：2011-10-04